[ARS] XBiotech Inc SEC Filing

Filing Impact

(No impact)

Filing Sentiment

(Neutral)

Form Type

ARS

Rhea-AI Filing Summary

07/07/2025 - 05:25 PM

ARS - XBiotech Inc

ARS Filing - XBiotech Inc

This filing is available as a PDF document.

Filing Type: ARS

Company: XBiotech Inc (XBIT)

Acceptance Date: 2025-07-07T17:25:01.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Xbiotech

NASDAQ:XBIT

XBIT Rankings

#6513 Ranked by Market Cap

N/A Ranked by Dividends

#41 Top Loser

XBIT Latest News

Dec 23, 2024

XBiotech Pauses Rheumatology program

Jun 18, 2024

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

Jan 4, 2024

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

Nov 14, 2023

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

Sep 26, 2023

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

XBIT Latest SEC Filings

Jul 7, 2025

[DEF 14A] XBiotech Inc Definitive Proxy Statement

Jun 24, 2025

[8-K] XBiotech Inc Reports Material Event

XBIT Stock Data

Market Cap 92.99M

Float 19.32M

Insiders Ownership 35.15%

Institutions Ownership 15.72%

Short Percent 3.42%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City AUSTIN